马来酸曲美布汀治疗肠易激综合征的疗效及安全性

The efficacy and safety of trimebutine maleate in the treatment of irritable bowel syndrome

目的 :临床验证马来酸曲美布汀 (舒丽启能 )治疗肠易激综合征 (IBS)的疗效及安全性。方法 :多中心开放基础上对照研究。选择IBS患者 6 4例 ,空白对照治疗 2周 ,15例临床症状缓解 ,49例进入舒丽启能治疗组 ,po ,2 0 0mg ,tid ,疗程 2周 ,观察腹痛、腹泻、排便异常、排便困难等症状变化。 结果 :舒丽启能对腹痛治疗有效率为91.8%。排便异常有效率为 89.8% ,腹泻有效率为 86 .6 % ,排便困难有效率为 81.8% ,总体评估总有效率为81.6 %。安全性研究未发现不良反应。结论 :舒丽启能治疗IBS是安全有效的。

Objective:To validate the clinical safety and efficacy of trimebutine maleate(Cerekinon) in treatment of irritable bowel syndrome(IBS).Methods:64 patients with IBS were recruited into the study.After 2 weeks placebo treatment 15 patients were excluded from the study due to symptoms relief.The balance of 49 patients were treated with Cerekinon 200mg,po,tid for 2 weeks.Results:After 2 weeks treatment,the following results were obtained:91.8% reduction in abdominal pain;89.8% reduction in abnormal defecation;86.6% reduction in diarrhoea;81.8% reduction in constipation;and a total effective rate 81.6%.No side effect was observed.Conclusion:Cerekinon is an effective agent for treatment of IBS. [